Forte Biosciences Surges 39% on argenx's $1.2B Bid

argenx's all-cash takeover offer of $7 per share values the San Diego biotech lab at $1.2 billion and delivers a 40% premium to Forte Biosciences shareholders.

argenx offered $7 per share in cash for Forte Biosciences, a 40% premium to the prior closing price.
The merger handshake values Forte at approximately $1.2 billion and sent shares up nearly 39% in Monday trading.
The deal extends argenx's push beyond its FcRn franchise into adjacent immunology and dermatology pipelines.

Lead

argenx SE announced Monday an agreement to acquire Forte Biosciences for $7.00 per share in an all-cash transaction worth approximately $1.2 billion, representing a 40% premium to Forte's Friday closing price. The merger handshake with the San Diego-based biotech lab triggered an immediate 39% surge in Forte shares, which opened the session near $6.95 before stabilizing just below the offer price — a spread consistent with a deal market that views regulatory and shareholder approval as routine rather than uncertain.

What Happened

The agreement, executed over the weekend and announced before U.S. equity markets opened, calls for argenx to acquire all outstanding shares of Forte Biosciences at $7.00 in cash per share. The biotech lab, which has focused on IL-17 and related immune pathways in inflammatory skin diseases, had been trading at roughly $5.04 ahead of the offer. The 40% premium is in line with the median acquisition premium seen across specialty biotech deals over the past two years and signals argenx's conviction in Forte's clinical and platform assets.

The boards of both companies have unanimously approved the transaction. No financing contingency was attached to the deal, reflecting argenx's strong balance sheet, which has been bolstered by accelerating global royalty and product revenue from efgartigimod across multiple autoimmune indications.

Market Reaction

FBRX shares jumped to $6.94 within minutes of the open — effectively pricing near the offer level and leaving the deal spread at roughly six cents, or under 1%, indicating high market confidence in deal completion. Volume ran more than 30 times the 90-day daily average in the first hour of trading. ARGX shares traded modestly lower in Amsterdam and on U.S. markets, a typical pattern when an acquirer deploys cash at a meaningful premium. The move in argenx was contained, however, suggesting investors broadly accepted management's strategic rationale.

Strategic Context

For argenx, the acquisition represents a calculated expansion of its immunology franchise. The Belgian biotech has built a leading position in FcRn-mediated autoimmune diseases through efgartigimod but has signaled intent to diversify its pipeline across immune-mediated dermatology, neurology, and rare disease. The Forte biotech lab assets fit squarely into that roadmap, offering differentiated IL-17 biology and a patient population where argenx has existing commercial infrastructure and physician relationships.

The merger handshake also reflects a broader consolidation wave in specialty biotech, where mid-cap acquirers with commercial revenues and strong balance sheets are selectively targeting clinical-stage companies whose assets have de-risked sufficiently for strategic buyers — even as the IPO window for early-stage biotechs remains narrow.

Forte's lead programs in inflammatory skin conditions, including atopic dermatitis and related indications, complement argenx's pipeline without creating direct internal competition, reducing the integration risk that has complicated some recent biotech mergers.

Geopolitical and Regulatory Dimension

The deal is structured as a straight cash merger and is expected to clear standard U.S. antitrust review without significant hurdles given the complementary — rather than overlapping — nature of the two companies' commercial footprints. Cross-border biotech M&A involving European acquirers and U.S. targets has attracted minimal Committee on Foreign Investment in the United States scrutiny when the strategic rationale is pipeline-driven rather than data- or defense-adjacent.

What Comes Next

The transaction is expected to close in the second half of 2026, subject to Forte shareholder approval and customary regulatory clearances. Once closed, Forte's pipeline will be integrated into argenx's immunology development organization. No immediate workforce reduction plan was announced, though integration of a biotech lab of Forte's size typically involves selective consolidation of overlapping functions within 12 to 18 months post-close.

Outlook

The $1.2 billion all-cash offer for Forte Biosciences solidifies argenx's position as one of the more active consolidators in mid-cap immunology, adding complementary IL-17-targeted assets at a premium that reflects both pipeline value and competitive scarcity. With the deal spread near zero, the market's verdict is clear: the merger handshake is expected to close on schedule, extending argenx's reach in specialty biotech while delivering immediate value to Forte shareholders.

Mentioned tickers: FBRX, ARGX

Deals }}